GlassScriptPhysician profile
Jonathan R Steen
NPI 1750543849
$685.33
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $161 · 2023: $19.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $146.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $69.18 | 2019-2020 | |
| Amgen INC. | $56.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.20 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $50.45 | 2019-2020 | |
| Tris Pharma INC | $35.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.86 | 2019 | |
| Neos Therapeutics, LP | $29.37 | 2019 | |
| Shire North American Group INC | $28.47 | 2019 | |
| Merck Sharp & Dohme LLC | $27.62 | 2019 | |
| Pfizer INC. | $23.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $22.70 | 2019 | |
| Abbvie INC. | $19.47 | 2023 | Vraylar |
| Mylan Specialty L.P. | $16.43 | 2019 | |
| Biogen, INC. | $15.23 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.63 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.06 | 2019 | |
| Novo Nordisk INC | $11.95 | 2020 | |
| Amarin Pharma, INC. | $11.70 | 2020 | |
| Glaxosmithkline, LLC. | $11.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Steen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.